Novartis Ag (NVSEF) Other Accumulated Expenses (2009 - 2026)

Novartis Ag has disclosed Other Accumulated Expenses across 10 years of filings, most recently posting -$100.0 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at -$100.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$100.0 million (changed N/A YoY), and the FY2023 annual result was $516.0 million, down 38.28% from the prior year.
• Other Accumulated Expenses came in at -$100.0 million for Q1 2026 at Novartis Ag, down from $516.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $836.0 million in Q4 2022 to a low of -$100.0 million in Q1 2026.
• The 3-year median for Other Accumulated Expenses is $516.0 million (2023), against an average of $417.3 million.
• Across the five-year window, Other Accumulated Expenses surged 35.06% in 2022 and sank 38.28% in 2023, its largest moves.
• Novartis Ag's Other Accumulated Expenses stood at $836.0 million in 2022, then tumbled by 38.28% to $516.0 million in 2023, then slumped by 119.38% to -$100.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at -$100.0 million (Q1 2026), $516.0 million (Q4 2023), and $836.0 million (Q4 2022), per Business Quant data.